Project Grant R16NS147984
Award Date 9/1/25
Completion Date 8/31/29
Dollars Obligated $131K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
West Haven, CT 06516, USA
Similar Awards
- This $452,375 federal Project Grant awarded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) supports research investigating the role of nuclear mechano-transduction in regulating gene expression and shaping the spatial landscape in glioblastoma (GBM). The 2-year research project, running from August 2025 to July 2027, will be conducted by The Trustees of Columbia...
- This $638,697 federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program supports research by the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University (CCLCM) to investigate the role of the SMARCA5 protein in the development and progression of glioblastoma, an aggressive type of brain cancer. The goal of the research is...
- This federal Project Grant award of $460,940 from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports research conducted by the University of Texas MD Anderson Cancer Center to investigate how genetic risk factors for glioma, a type of brain cancer, impact neurodevelopmental processes and potentially promote tumor formation. The research leverages human...
- This federal Project Grant award of $429,000 from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, aims to explore the mechanism of Notch inhibition resistance in glioblastoma (GBM) cancer stem-like cells. The goal is to develop novel therapies for this deadly brain cancer. The research project, led by the Regents of the University of Michigan, will identify GBM...
- The National Institute of Neurological Disorders and Stroke (NINDS), through its Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853), awarded a $420,251 Project Grant to Brigham & Women's Hospital Inc. on May 6, 2025. The grant supports the development of an encapsulated cell-based oncolytic virus therapy for the treatment of glioblastoma (GBM), the most lethal primary brain tumor. The research aims to enhance the therapeutic efficacy of engineered...
- This $245,434 federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) supports research at the University of Pennsylvania to map the neural circuit connectivity of human high-grade glioma brain tumors in a mouse model. The goal is to define the whole-brain inputs onto glioblastoma cells using monosynaptic tracing techniques to understand how neuronal...
- The National Institute of Neurological Disorders and Stroke (NINDS) awarded a 24-month, $430,375 Project Grant (CFDA 93.853) to Emory University to develop human organoid models for pediatric high-grade gliomas (PHGGs). The research aims to 1) create PHGG organoid models using human patient-derived cancer stem cells and 2) model how interactions between PHGG cells and the human neural microenvironment affect responses to tyrosine kinase inhibitors and other anti-tumor drugs. The goal is to...
- This $442,750 federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program supports research to induce and image extrachromosomal DNA (ecDNA) in human glioblastoma cells. The primary goals are to determine if EGFR ecDNA causally fuels glioblastoma tumorigenesis, elucidate how centromere-less ecDNA propagates to daughter cells during mitosis, and...
- This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), part of the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) grant program, will fund research to target cell-scaffolding proteins that contribute to radioresistance in glioblastoma, an aggressive brain cancer. The $448,250 award to The Research Foundation For The State University Of New York, operating as Upstate Medical Center, will support a 2-year...
- This Project Grant award of $163,640 from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) supports research to develop novel non-viral gene delivery platforms for the treatment of glioblastoma, an aggressive brain cancer. The study aims to investigate the use of brain-penetrating nanoparticles modified to target tumor cells, and to further optimize gene delivery through focused ultrasound treatment. The research is being conducted at the University of Virginia,...